The authors report the development of a high-throughput screen for inhibitors of Streptococcus pneumoniae transcription and translation (TT) using a luciferase reporter, and the secondary assays used to determine the biochemical spectrum of activity and bacterial specificity. More than 220,000 compounds were screened in mixtures of 10 compounds per well, with 10,000 picks selected for further study. False-positive hits from inhibition of luciferase activity were an extremely common artifact. After filtering luciferase inhibitors and several known classes of antibiotics, approximately 50 hits remained. These compounds were examined for their ability to inhibit Escherichia coli TT, uncoupled S. pneumoniae translation or transcription, rabbit reticulocyte translation, and in vitro toxicity in human and bacterial cells. One of these compounds had the desired profile of broad-spectrum biochemical activity in bacteria and selectivity versus mammalian biochemical and whole-cell assays.
INTRODUCTION
T HE CLINICALLY USEFUL LIFETIME of an antibacterial is limited by the development of bacterial resistance, creating a constant need for new antimicrobial therapies. As part of a comprehensive strategy to discover small-molecule antibacterial lead compounds with novel structures, we targeted the biochemical pathways of bacterial transcription and translation (TT). Although coupled bacterial transcription/translation assays are being used less often in high-throughput screening (HTS) for antimicrobial compounds as researchers focus on smaller, more easily characterized enzyme targets, this method should be included in any comprehensive antibacterial discovery strategy. Because numerous antibacterial classes, including macrolides/ketolides, amino-glycosides, tetracyclines, rifamycins, and oxazolidinones, inhibit these pathways, we reasoned that they might contain additional valid antimicrobial targets not exploited by the known classes.
Bacterial cell extracts have been used for many years to study transcription and translation in Escherichia coli. 1, 2 We felt, and recent studies 3 suggest, that there may be advantages to developing screening assays using extracts from clinically relevant bacteria. To learn whether our small-molecule library contained inhibitors of bacterial TT, we designed a coupled assay using an extract from the pathogen Streptococcus pneumoniae to maximize the probability that leads discovered would inhibit growth of this clinically relevant bacterium. The limited published literature on the subject suggests that an E. coli TT assay would not yield the same resulting hits from an identical compound collection as would an assay using cell extracts from a gram-positive bacterium. In the only other gram-positive luciferase reporter TT assay published, 3 the authors report a 60-fold difference in IC 50 for tetracycline between their S. aureus TT assay and a corresponding E. coli TT assay. We observed a 200-fold difference between the S. pneumoniae TT and E. coli TT IC 50 values (see Table 1 ) for lincomycin. Even if the ultimate goal is the discovery of a broad-spectrum antibacterial agent, the use of a "model" system such as an E. coli extract in a typical high-stringency, high-throughput screen could accidentally rule out compounds that may be only slightly weaker in the model system as compared to a more relevant extract from a target pathogen. In addition, it has been observed that minimum inhibitory concentrations (MICs) for a given pathogen are better predicted by that pathogen's S30 extract than by that of another organism. 3 To quickly determine which screening hits would be good candidates for further optimization, we used a battery of secondary assays both to identify artifactual inhibitors and to prioritize the candidates on the basis of bacterial specificity, ability to inhibit coupled TT in gram-negative extracts, cytotoxicity in human cells, and ability to inhibit bacterial growth in vitro. Here we report the development of a microplate assay for coupled S. pneumoniae TT using a luciferase reporter plasmid, as well as subsequent experiments used to characterize the resulting hits.
MATERIALS AND METHODS

Construction of luciferase reporter plasmid
The pA promoter region from pEVP3 4 was subcloned as a KpnI-BglII fragment into pSP-luc+ (Promega Corp., Madison, WI) to generate pAS10. A new Shine-Dalgarno (SD) site composed of a consensus sequence from S. pneumoniae genes 5 was added, and plasmids containing several different spacings between the SD and the methionine start codon were constructed; the one generating the optimal signal, pAS10rbs3, is shown in Figure 1 .
Preparation of S30 extract
The procedure was adapted from those of Mackie et al. 6 and Legault-Demare and Chambliss. 7 Four liters of THY media (containing 30 g Todd-Hewitt Broth and 5 g Yeast Extract [Difco] per liter) in 800-mL aliquots were each inoculated with 48-mL overnight cultures of S. pneumoniae (ATCC 49619) and grown without shaking at 37°C to an OD 600 of 0.4 to 0.5. Cultures were chilled in an ethanol/ice bath for 30 min, and cells were pelleted at 6000 g. Cell pellets were pooled and washed twice with 500 mL of a cold high-salt buffer (10 mM Tris-HCl [pH 7.5], 1 M NH 4 Cl, 15 mM Mg-acetate, 50 mM KCl, 6 mM 2-mercaptoethanol) and once with 500 mL of a low-salt buffer (same as the high-salt buffer, except 60 mM NH 4 Cl). Cell pellets were stored at -80°C. Frozen cells were thawed 30 min in ice water and resuspended in 50 mL low-salt buffer. Phenylmethylsulfonyl fluoride and diisopropyl fluorophosphate (Sigma, St. Louis, MO) were added to final concentrations of 1 mM and 0.1 mM, respectively, along with 1500 units of an RNase inhibitor (Gibco BRL, Rockville, MD). The cells were lysed by French press at 12,500 psi, followed by centrifugation at 4°C for 10 min at 14,000 g. The supernatant was centrifuged at 4°C for 40 min at 30,000 g. The resulting supernatant was dialyzed at 4°C against 3 changes (1 L each) of low-salt buffer, twice for 1 h, then once overnight. The resulting extract was aliquoted, frozen in dry ice/ethanol, and stored at -80°C. Each batch of extract was tested against a panel of 17 different transcription and translation inhibitors and several negative controls to ensure batch-to-batch consistency.
S. pneumoniae transcription/translation assay (luciferase readout)
Premix and amino acid mix reagents from a commercial (Promega Corp., Madison, WI) E. coli transcription/translation assay were used in both S. pneumoniae assays. The luciferase readout assay was designed for HTS in 96-well half-well black plates (Costar #3694, Corning, Inc., Acton, MA) in a final volume of 16.5 µL. Test compounds were dispensed from DMSO-dissolved stocks to produce a nominal final screening concentration of 10 µM and dried in a vacuum centrifuge at 42°C for 15 min. Diluted S30 extract-composed of 2.33 µL S30 extract, 1.17 µL buffer A (10 mM Tris-HCl [pH 7.5], 60 mM NH 4 Cl, 15 mM Mg(AcO) 2 , 50 mM KCl, and 6 mM 2-mercaptoethanol), and 5 µL H 2 O-was added to each well. This mixture was shaken for 10 min at 25°C, followed by addition of a mix containing 5 µL Premix (consisting of 500 mM potassium acetate, 87.5 mM Tris-acetate [pH 8.0], 60 mM ammonium acetate, 50 µg/mL folinic acid, 2 mM isopropyl β-D-1-thiogalactopyranoside [IPTG], 5 mM dithiothreitol, 87.5 mg/ mL PEG-8000, 1.25 mM each rNTP, 50 mM phosphoenolpyruvate, 2.5 mM cAMP, and 0.124% sodium azide), 0.5 µL (1 µg/µL) pAS10rbs3, 1.25 µL 1 mM amino acid mix, and 1.25 µL H 2 O. Plates were then incubated a further 2 h at 25°C with shaking. Reactions were stopped by adding 20 µL of 20-µg/mL kanamycin to each well. Plates were read on a Wallac Victor2, with each well read immediately after injection of 50 µL of luciferin reagent, containing 20 mM tricine, 2.67 mM MgSO 4 , 0.1 mM ethylenediaminetetraacetic acid (EDTA), 33.3 mM dithiothreitol (DTT), 270 µM coenzyme A (Sigma), 470 µM beetle luciferin (Promega), 530 µM adenosine triphosphate (ATP), and 1.07 mM MgCO 3 , adjusted to pH 7.8 with NaOH.
S. pneumoniae transcription/translation assay (radiolabel readout)
The radiolabeled gel assay was done as described above, with the following alterations. Each reaction (60 µL) was done in a 1.5-mL polypropylene tube and included 14 µL S30, 7 µL buffer A, 8.6 µL H 2 O, 3.5 µL (1 µg/µL) pAS10rbs3, 20 µL Premix, 5 µL amino acid mix (-Met), and 24 µCi [ 35 S]Methionine (1000 Ci/ mmol; Amersham Pharmacia, Piscataway, NJ). Reactions were done in duplicate, then pooled and split, with half stopped and read in triplicate as for the standard luciferase assay and the other half stopped with the addition of 260 µL cold acetone, incubated on ice 15 min, and centrifuged at 14,000 rpm for 5 min. The supernatant was aspirated, and the pellets were dried in a vacuum centrifuge. Pellets were dissolved in an 80-µL Laemmli sample buffer (Bio-Rad, Hercules, CA), and 10 µL/lane was run on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel. Visualization and quantitation of bands were done using a Molecular Dynamics Storm 860 phosphorimager with the supplied software.
Direct luciferase inhibition assay
Two sets of reactions containing the S. pneumoniae TT assay reagents (an equal number of wells in each set) were prepared as described above: set 1 contained only the normal assay reagents; set 2 contained assay reagents and dried test compounds. After a 2h incubation, all the reactions were stopped with kanamycin. Reaction mixtures from wells in set 1 were transferred to a new plate containing the same set of dried compounds as used in set 2. Both sets were incubated an additional 2 h and read after the addition of luciferin, as usual. Inhibitors of transcription or translation produced signal reductions only in set 2 samples and not in set 1 samples, whereas luciferase artifacts caused signal diminution in both set 1 and set 2 reactions.
Rabbit reticulocyte lysate translation assay (luciferase readout)
The Promega Rabbit Reticulocyte Lysate system was used as recommended in the Promega protocol with the following exceptions: assays were done in a 16.5-µL total volume, with all reagents scaled appropriately to maintain the recommended concentrations, except the control mRNA, for which the final concentration (33 ng) was 10-fold less than that described. Then, 11.5 µL of lysate was added to dried compound in 96-well plates, as described for the S. pneumoniae assay. The remaining 5 µL consisted of 0.033 µL luciferase control mRNA (33 ng), 0.33 µL 1 mM amino acid mix, and water. Plates were incubated 2 h with shaking at 25°C. Reactions were stopped with 20 µL of 100 µg/mL cycloheximide and read as described above.
E. coli transcription/translation assay ( -galactosidase readout)
Reagents and methods from the Promega E. coli S30 Extract System for Circular DNA were used, with the following alterations. Reactions were done in 96-well clear plates (Falcon #3075, Becton Dickinson, Lincoln Park, NJ) in a final volume of 30 µL. For each well, the 3-µL S30 extract was diluted with 7 µL H 2 O and added to plates containing dried test compounds prepared as described above. Plates were shaken for 10 min at 25°C, followed by addition of a mix containing 12 µL Premix, 0.6 µL (0.5 µg/µL) pGEM-β-Gal, 3 µL 1 mM amino acid mix, and 4.4 µL H 2 O. Reactions were incubated 2 h with shaking at 25°C and stopped by adding 20 µL of 20-µg/mL kanamycin to each well. The βgalactosidase activity was assayed by the addition of 50-µL 2x assay buffer (200 mM NaPO 3 − [pH 7.3], 2 mM MgCl 2 , 100 mM 2mercaptoethanol, 1.33 mg/mL o-nitrophenyl-βgalactopyranoside) and incubated 20 min at 37°C. Then, βgalactosidase activity was stopped with the addition of 150 µL 1 M Na 2 CO 3 , and plates were read for absorbance at 420 nm on a Wallac Victor2.
S. pneumoniae translation assay (luciferase readout)
This assay was performed essentially as the transcription/ translation assay and was capable of transcription as well as translation. We limited the activity to translation only with the following changes to the TT procedure. Messenger RNA encoding the luciferase gene was synthesized using the Promega RiboMAX SP6 in vitro transcription system and used in place of the pAS10rbs3 plasmid. Each batch of mRNA was assayed for total signal generated prior to use and the assay concentration adjusted accordingly; about 500 ng mRNA per well was typical.
Cytotoxicity testing
Compound cytotoxicity was evaluated against the human B lymphoma cell line, Jijoye (ATCC, Rockville, MD). Log phase cells were suspended in fresh culture medium at a density of 1 × 10 6 cells/mL and plated at 200 µL/well in 96-well plates (Corning #3596). Compounds were dissolved in DMSO (Sigma), serially diluted, and added to the cells over a final concentration range from 0.8 to 100 µg/mL while maintaining a final DMSO concentration of 1%. The cell plates were then incubated at 37°C/5% CO 2 for approximately 24 h. The effect on cellular respiration was evaluated using Alamar Blue. 8 Upon addition of 10 µL/well of prewarmed Alamar Blue reagent (BioSource International, Camarillo, CA), the cell plates were incubated for an additional 4 h and then fluorometrically assayed at 530-nm (excitation)/572-nm (emission) wavelengths on a Wallac Victor2. Control wells included untreated cells (with 1% DMSO), medium only (for background subtraction), and known toxic control compounds run in the same way as the test compounds. 
S. pneumoniae transcription assay (radiolabeled readout)
Compounds were tested at 10 and 30 µM in V-bottom polypropylene 96-well plates (Costar #3363) after drying as described above. S30 extract was dispensed at 2.3 µL per well and incubated at room temperature for 10 min. The remainder of the reaction mix was composed of 1 µg pAS10rbs3, 3.5 µL Premix (Promega), 1 µL of 1 mCi/mL 3 H-UTP, 30 to 60 Ci/mmol (Amersham Pharmacia); and water for a volume of 7.5 µL. Final volume per well was 9.8 µL. Plates were covered with plastic wrap and incubated at room temperature for 1 h. Prior to completion of incubation, 200 µL of 5% trichloroacetic acid (TCA) was added to the wells of a Millipore MultiScreen-FB filter plate. At 1 h, the total volume of the reaction was pipetted into the TCA on the filter plate and refrigerated at least 1 h, then vacuumed dry on a plate manifold. Plates were washed 3 times with 200 µL 5% TCA followed by a final 200-µL wash with 95% ethanol. Excess ethanol was removed by blotting, and plates were allowed to air dry. For counting, 100 µL of Wallac Optiphase "SuperMix" scintillant was added to each well. Data were generated using a Wallac Trilux 1450 Microbeta Scintillation Counter.
Antibacterial susceptibility determination (MICs)
The susceptibilities of S. pneumoniae ATCC 6303 (Manassas, VA) to test compounds were determined by broth microdilution as described by the National Commission for Clinical Laboratory Standards (NCCLS); quality control met NCCLS standards. 9
RESULTS AND DISCUSSION
Construction of S. pneumoniae luciferase reporter plasmid
The plasmid pSP-luc+ (Promega) containing an engineered version of the firefly luciferase gene and an SP6 promoter is the parent for the S. pneumoniae luciferase expression vector. The S. pneumoniae ami promoter, pA, was chosen to drive transcription because it is well understood and was readily available. The SP6 promoter of pSP-luc+ was retained for use in the in vitro transcription reactions to produce an mRNA template for the S. pneumoniae translation assay. To optimize expression of luciferase, the consensus SD site was inserted with varying spacings between the 3′ end of the SD and the initiator methionine codon. Compared to published data, a surprisingly short spacing produced an optimal signal in this system. One study reports optimal spacings (having > 80% of maximal expression activity; our definition) between the SD and initiation codon of 6 to 9 bases for E. coli, 10 and another 11 reports an optimum of between 6 and 8 bases for E. coli and 7 to 8 bases for Bacillus subtilis. Spacings for pAS10rbs1, pAS10rbs2, and pAS10rbs3 were 11, 7, and 4 bases, respectively. Following the model seen in E. coli and the grampositive B. subtilis, one might expect the maximal expression of luciferase from pAS10rbs2, with a 7-base spacing, rather than the shorter 4-base spacing in pAS10rbs3, which in fact produced the maximal protein expression of the 3 plasmids using the S. pneumoniae TT radiolabeled gel assay (data not shown). We speculate that either the spacing optima are different for S. pneumoniae than for the bacteria previously studied, or perhaps the upstream or downstream sequences play a role in changing spacing requirements (none of the studies referenced used luciferase as a reporter).
Development of the S. pneumoniae transcription/ translation assay
The procedure for preparation of S. pneumoniae S30 extracts was adapted from published procedures for E. coli. In addition to changing bacterial growth conditions to optimize for Streptococcus, we added a high-salt wash of the bacterial pellet and included protease inhibitors phenylmethylsulfonyl fluoride and diisopropyl fluorophosphate to limit extracellular protease activity common for some gram-positive bacteria. 12 Each batch of S30 extract was tested against a panel of control antibiotics known to inhibit bacterial transcription or translation. Control antibiotics were selected from many different classes to ensure that the assay would detect inhibitors with widely varied mechanisms of action. These included macrolides, aminoglycosides, tetracyclines, and chloramphenicol, which block bacterial translation by binding to and inhibiting ribosome function, and kirromycin and fusidic acid, which inhibit translation by binding to the ribosomal elongation factors EF-Tu and EF-G, respectively. Also included were rifampicin and streptolydigin, which block bacterial transcription by inhibiting RNA polymerase. Although the luminescence signal generated varied by as much as 6-fold among batches of extract, batch-to-batch variability in inhibition values was low and produced no more than a 2-fold difference in IC 50 from one S30 batch to another (data not shown).
Half-well plates and a total reaction volume of 16.5 µL were used to minimize reagent consumption. Reaction signal reached a plateau above 2.5 µL of the S30 extract (Fig. 2 ). An extract concentration slightly below this was selected to ensure sensitive detection of inhibitors. In the absence of a plasmid template, the signal remained at the background, even at the highest concentrations of S30. A plot of luminescence signal generated versus plasmid template concentration was biphasic and centered at approximately 500 ng/well (Fig. 2) , which was chosen for the assay. Assay noise is nearly nonexistent, as is typical for luciferase assays, and thus the signal-to-noise ratio increases nearly in proportion with the overall signal. It could be argued that the variation in light signal from batch to batch of the S30 extract makes it necessary to reformulate the assay for each batch of extract produced. We felt that this was unnecessary because the IC 50 values of control compounds did not vary greatly with different S30 batches.
The scatter plot of percent inhibition versus nominal screening concentration (Fig. 3) shows S. pneumoniae TT (luciferase) results from 3 identical compound mixture plates (12 compounds per well) from Abbott's compound library. Control antibiotics were added to individual wells at the same concentration as the library compounds into which they were mixed. We observed that 10 µM (each compound) was the only screening concentration at which all the positive controls were separated from the main body of the scatter. At this concentration, a number of other wells appeared above the scatter as well. Most of these wells contained macrolide derivatives (common in the Abbott library), which are likely to be the cause of the inhibition seen in those wells. At 1 µM, highly active compounds such as erythromycin (IC 50 = 0.1 µM) are clearly differentiated from the bulk of compounds tested, but chloramphenicol (IC 50 = 4 µM) is indistinguishable from background scatter, and at 25 µM, a large number of samples show high inhibition, most likely due to the combined weak activity of multiple compounds in the mixtures. The screening concentration was set at 10 µM because this was the lowest compound concentration for which all the positive controls were clearly identifiable as inhibitors.
IC 50 values were determined for 8 known translation or transcription inhibitors in the S. pneumoniae TT assay (Table 1) ; representative examples of inhibition curves are shown in Figure 4 . Streptomycin is the most active of the set (IC 50 = 0.03 µM), and chloramphenicol is the least active (IC 50 = 4 µM). Cycloheximide, a eukaryotic translation-specific inhibitor, did not inhibit the reaction when tested at concentrations up to 25 µM. For translation inhibitors, nearly identical curves were observed in the uncoupled S. pneumoniae translation assay. Rifampicin, a transcription inhibitor, was inactive (IC 50 > 100 µM).
Secondary assay evaluation
A battery of secondary assays was established (Table 1) to characterize the hits and help identify those compounds with the highest probability for success as antibacterial leads. These assays included experiments to detect inhibitors of the assay readout (luciferase), coupled transcription/translation with extracts from the gram-negative E. coli to assess the biochemical "spectrum" of activity, uncoupled S. pneumoniae assays (1 for transcription and 1 for translation), a eukaryotic translation assay to assess biochemical selectivity, and a radiolabel readout S. pneumoniae TT assay, which provided a direct visualization of translation products.
The direct luciferase assay determines whether a compound added to the S. pneumoniae TT assay medium can inhibit luminescence either by inhibiting luciferase enzymatic activity or by luminescence quenching after synthesis of the luciferase reporter is al- ready complete. Compounds producing false positives this way in the S. pneumoniae TT screen were very common. We chose to mimic as closely as possible the conditions of the screen for the direct luciferase assay because testing of the luciferase enzyme separate from the other components in the TT assay does not reliably detect all of these artifactual inhibitors (data not shown). An E. coli TT assay using a β-galactosidase rather than a luciferase reporter was used as an interchangeable approach to eliminating luciferase artifacts. Because inhibitors with broad-spectrum biochemical activity are of the most interest, this allowed for the filtering of luciferase inhibitors and narrow-spectrum inhibitors in a single experiment. Typically, no further data were collected for analogs that did not have activity in this assay, as we felt that they were less likely to ultimately yield a broad-spectrum antibacterial lead. The set of antibiotics described above was tested in the E. coli TT assay using the same compound dilutions. Results are shown in Figure 4 and Table 1 . The IC 50 ratio for E. coli/S. pneumoniae TT varies from 0.25 for streptomycin to 7.5 for tetracycline, with lincomycin as an outlier having a ratio of 200. This difference for lincomycin correlates well with the poor gram-negative activity of the related lincosamide, clindamycin. 13 After elimination of luciferase artifacts and selection for broadspectrum biochemical activity, hits from the S. pneumoniae TT screen were further characterized using the S. pneumoniae translation and S. pneumoniae transcription assays. Inhibitors of S. pneumoniae translation were tested for biochemical selectivity in the rabbit reticulocyte lysate translation assay. To accurately assess the relative potency versus bacterial translation, we tested compounds in this assay and the S. pneumoniae translation assay simultaneously from identical dilutions. This also ensured elimination of false negatives due to compound degradation or an improper compound dilution. The eukaryotic-specific translation inhibitor cycloheximide is highly active (IC 50 = 0.3 µM). The control antibiotics described above were also tested in this assay, again from the same dilution set ( Fig. 5 and Table 1 ), and all were weak or inactive. 
Screening results
A library containing 220,800 compounds was assayed in duplicate in nonidentical mixtures containing 10 compounds per well at a nominal final concentration of 10 µM each compound. In the mixing and deconvolution strategy, each compound appeared in 2 wells of the same plate, mixed with 9 other compounds in each instance. 14 Data were analyzed on a plate-by-plate basis. Wells with luminescence values significantly separated from the scatter were selected for follow-up; this consisted of a total of 10,000 compounds. Because the Abbott compound library contains a large number of active macrolides (> 1% of total library) in which we were uninterested, we opted to remove from consideration the contents of those wells whose activity could be ascribed to them. Because of the mixing strategy used and the high percentage of active macrolides present, it was statistically likely that any picks would deconvolute as active due to the likelihood of an active macrolide being present in 1 of the 10 deconvolution wells. Because we chose to pick aggressively, we were not surprised to find that after this filtering, followed by retesting at 20 µM, only 2,832 candidates remained.
Initial secondary testing in the direct luciferase inhibition assay showed that luciferase artifacts were very common; a typical test run indicated that > 80% of the total compounds tested positive for luciferase inhibition under the described assay conditions. Subsequently, the direct luciferase inhibition assay was replaced with the E. coli TT β-galactosidase readout assay as the initial secondary screen to filter luciferase artifacts and narrow-spectrum inhibitors simultaneously. As expected, the vast majority (> 95%) of compounds tested in this assay showed no activity because luciferase artifacts, as well as S. pneumoniae-specific inhibitors, do not produce inhibition. To ensure that compounds that inhibited weakly in the E. coli system would not be discarded, this assay was run at a nominal concentration of 25 to 30 µM, in duplicate, and com-pounds that gave 30% or greater inhibition were selected for further examination. After evaluation with these 2 assays, a relatively small number of compounds were retained for further examination. After elimination of luciferase artifacts, compounds structurally related to known translation or transcription inhibitors, and/or narrow-spectrum inhibitors, approximately 50 of the original 2832 hits remained as bona fide inhibitors of translation or transcription.
All of the 50 inhibitors tested in the uncoupled assays were shown to be specific for translation. Many of these compounds, although genuine translation inhibitors, proved to be nonspecific with regard to eukaryotic translation, inhibiting the rabbit translation assay in addition to the bacterial assays. Members of chemical classes having known liabilities were also eliminated from consideration, leaving a single compound, A-72310. A-72310 was the only hit with broad-spectrum biochemical activity, biochemical selectivity versus the rabbit reticulocyte lysate assay, and low human B-cell cytotoxicity.
Representative examples of the screening hits illustrate the range of biochemical profiles observed ( Table 1 ). The compound A-209106.0 inhibits in both S. pneumoniae and E. coli TT assays. However, it also inhibits the rabbit reticulocyte translation assay and is cytotoxic. This profile is consistent with a biochemically nonselective translation inhibitor. A-84655.0 was confirmed to be a luciferase artifact using the direct luciferase assay. A-85123.0 exhibits strong activity in the S. pneumoniae TT assay and does not inhibit luciferase but has very weak activity in the corresponding E. coli assay; hits with this profile are consistent with grampositive-specific TT inhibition. An example of a known TT antibiotic that hit in the screen was Blasticidin S (A-58012), an inhibitor of both prokaryotic and eukaryotic peptidyltransferase, 15, 16 which, accordingly, inhibits in both bacterial and rabbit reticulocyte translation. Although A-91664 exhibits reproducible activity in the S. pneumoniae TT assay, the quaternary ammonium is a structural feature associated with toxicity problems. 17 A-72310 was the only screening hit with an optimal profile in the secondary assays. We have subsequently shown that A-72310 inhibits translation in gram-positive and gram-negative extracts and inhibits bacterial growth in vitro by this mechanism. 18 This discovery led to extensive medicinal chemistry, resulting in a novel ribosome inhibitor (NRI) class of compounds, details of which will be published elsewhere.
The above study describes a comprehensive strategy for the discovery of novel inhibitors of bacterial translation or transcription, along with the secondary assays used to characterize and prioritize discovered leads. Many of the reagents and secondary assays are commercially available and easily adaptable to high-throughput formats. 
